Literature DB >> 2571292

Rilmenidine: a novel antihypertensive agent.

M E Safar1.   

Abstract

Rilmenidine is a novel antihypertensive agent related to alpha 2-agonists. Pharmacologic and clinical data concerning efficacy and acceptability of rilmenidine, its effects on physiologic functions, and hypothesis of mechanism of action are described in this report. The dominant aspect of rilmenidine is the observed dissociation at therapeutic doses between antihypertensive and central effects. In this respect, several findings resulting from fundamental pharmacology, clinical pharmacology, and therapeutics differentiate rilmenidine from clonidine and related drugs. Hypotheses to explain the results observed with rilmenidine involve unknown properties that could counteract with the alpha 2-adrenoceptor-mediated sedation, respective contribution of central and peripheral components to the activity of rilmenidine, and possible contribution of imidazoline receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571292     DOI: 10.1016/0002-9343(89)90501-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease.

Authors:  Claudia Rose; Fiona M Menzies; Maurizio Renna; Abraham Acevedo-Arozena; Silvia Corrochano; Oana Sadiq; Steve D Brown; David C Rubinsztein
Journal:  Hum Mol Genet       Date:  2010-02-27       Impact factor: 6.150

Review 2.  Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension.

Authors:  P Chrisp; D Faulds
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

3.  A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.

Authors:  P Ernsberger; M A Haxhiu; L M Graff; L A Collins; I Dreshaj; D L Grove; M E Graves; S G Schäfer; M O Christen
Journal:  Cardiovasc Drugs Ther       Date:  1994-03       Impact factor: 3.727

4.  Electrophysiological effects of intravenous rilmenidine in man.

Authors:  J Tonet; C Guillet; G Jondeau; F Poulain; P Vivet; R Frank; Y Grosgogeat
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.